<p>Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BMY usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Bristol-Myers Squibb. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 55% leaning bullish and 22% bearish. Among these notable options, 2 are puts, totaling $924,240, and 7 are calls, amounting to $366,072.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $52.5 for Bristol-Myers Squibb over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Bristol-Myers Squibb stands at 1396.11, with a total volume reaching 4,025.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bristol-Myers Squibb, situated within the strike price corridor from $25.0 to $52.5, throughout the last 30 days.</p>
<h3>Bristol-Myers Squibb Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767376873_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767376873_0.png"/></p>

<h3>Noteworthy Options Activity:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/15/28</td>
<td>$4.95</td>
<td>$4.05</td>
<td>$4.35</td>
<td>$40.00</td>
<td>$863.0K</td>
<td>2</td>
<td>1.9K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$12.0</td>
<td>$11.85</td>
<td>$12.0</td>
<td>$43.00</td>
<td>$122.4K</td>
<td>620</td>
<td>105</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$0.36</td>
<td>$0.23</td>
<td>$0.34</td>
<td>$40.00</td>
<td>$61.2K</td>
<td>7.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/15/28</td>
<td>$24.35</td>
<td>$23.25</td>
<td>$24.1</td>
<td>$30.00</td>
<td>$48.2K</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.7</td>
<td>$27.7</td>
<td>$28.2</td>
<td>$25.00</td>
<td>$45.1K</td>
<td>971</td>
<td>16</td>
</tr>
</tbody>
</table><p></p>
<h3>About Bristol-Myers Squibb</h3>
<p>Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.</p>
<h3>Present Market Standing of Bristol-Myers Squibb</h3>
<ul>
<li>With a trading volume of 3,536,753, the price of BMY is down by -0.64%, reaching $53.59.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>Expert Opinions on Bristol-Myers Squibb</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $53.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* An analyst from B of A Securities upgraded its action to Buy with a price target of $61. 
* Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Bristol-Myers Squibb with a target price of $55. 
* An analyst from Scotiabank persists with their Sector Perform rating on Bristol-Myers Squibb, maintaining a target price of $53. 
* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Underweight rating for Bristol-Myers Squibb, targeting a price of $37. 
* In a positive move, an analyst from Guggenheim has upgraded their rating to Buy and adjusted the price target to $62. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from Benzinga Pro.</p>

<p>Bristol-Myers Squibb (NYSE:BMY) has seen significant bullish options activity, with 55% of investors leaning bullish. The projected price range for the stock is between $25.0 and $52.5. Current trading volume is 4,025, with an average open interest of 1,396. Analysts have varying opinions, with target prices ranging from $37 to $62. The stock is currently priced at $53.59, down 0.64%. The next earnings report is due in 34 days. Investors are advised to stay informed about options trading risks and market movements.</p>

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?